Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas

European Journal of Endocrinology, 07/08/2013

Auriemma RS et al. – Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease (PD), whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia. CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first five years of treatment.